These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24598781)

  • 1. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome.
    Blondel S; Jaskowiak AL; Egesipe AL; Le Corf A; Navarro C; Cordette V; Martinat C; Laabi Y; Djabali K; de Sandre-Giovannoli A; Levy N; Peschanski M; Nissan X
    Stem Cells Transl Med; 2014 Apr; 3(4):510-9. PubMed ID: 24598781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
    Gordon LB; Massaro J; D'Agostino RB; Campbell SE; Brazier J; Brown WT; Kleinman ME; Kieran MW;
    Circulation; 2014 Jul; 130(1):27-34. PubMed ID: 24795390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rejuvenating premature aging.
    Meshorer E; Gruenbaum Y
    Nat Med; 2008 Jul; 14(7):713-5. PubMed ID: 18607367
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
    Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
    Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
    Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
    Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
    Bifulco M; D'Alessandro A; Paladino S; Malfitano AM; Notarnicola M; Caruso MG; Laezza C
    FEBS J; 2013 Dec; 280(23):6223-32. PubMed ID: 24112551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
    Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
    Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prelamin A farnesylation and progeroid syndromes.
    Young SG; Meta M; Yang SH; Fong LG
    J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hutchinson-Gilford progeria syndrome as a model for vascular aging.
    Brassard JA; Fekete N; Garnier A; Hoesli CA
    Biogerontology; 2016 Feb; 17(1):129-45. PubMed ID: 26330290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome.
    Liu GH; Barkho BZ; Ruiz S; Diep D; Qu J; Yang SL; Panopoulos AD; Suzuki K; Kurian L; Walsh C; Thompson J; Boue S; Fung HL; Sancho-Martinez I; Zhang K; Yates J; Izpisua Belmonte JC
    Nature; 2011 Apr; 472(7342):221-5. PubMed ID: 21346760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished Canonical β-Catenin Signaling During Osteoblast Differentiation Contributes to Osteopenia in Progeria.
    Choi JY; Lai JK; Xiong ZM; Ren M; Moorer MC; Stains JP; Cao K
    J Bone Miner Res; 2018 Nov; 33(11):2059-2070. PubMed ID: 30001457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
    Pellegrini C; Columbaro M; Capanni C; D'Apice MR; Cavallo C; Murdocca M; Lattanzi G; Squarzoni S
    Oncotarget; 2015 Oct; 6(30):29914-28. PubMed ID: 26359359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
    Oshima J; Hisama FM; Martin GM
    Circulation; 2014 Jul; 130(1):4-6. PubMed ID: 24795391
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.